Most Read Articles
Audrey Abella, 03 Sep 2020
Interim analyses of the INBUILD trial presented at ATS 2020 continue to reflect the benefit of the tyrosine kinase inhibitor nintedanib for individuals with progressive fibrosing interstitial lung diseases (ILDs).
28 Aug 2020
Cơ quan Quản lý Thực phẩm và Dược phẩm Hoa Kỳ (FDA) đã cho phép “Hệ thống làm nóng thuốc lá IQOS” của Philip Morris Products S.A. được kinh doanh dưới hình thức sản phẩm thuốc lá điều chỉnh nguy cơ (Modified Risk Tobacco Products - MRTP) với thông tin “giảm thiểu phơi nhiễm” của cơ thể với chất độc hại.
28 Aug 2020
The U.S. Food and Drug Administration (FDA) has authorized the marketing of Philip Morris Products S.A.’s “IQOS Tobacco Heating System” as modified risk tobacco products (MRTP) with the “exposure modification” order.
Pearl Toh, 5 days ago
Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.

The US.FDA. Authorizes the Marketing of IQOS Tobacco Heating System with “Reduced Exposure” Information

28 Aug 2020
The U.S. Food and Drug Administration (FDA) has authorized the marketing of Philip Morris Products S.A.’s “IQOS Tobacco Heating System”* as modified risk tobacco products (MRTP) with the “exposure modification” order.
This is the first tobacco product that has ever been authorized by the FDA to be marketed with the information of “reduced exposure” (of the body to harmful chemicals). The authorization permits the marketing of a product as it contains a reduced level of a substance or it presents a reduced exposure to a substance or as it is free of a substance, and the issuance of the order is expected to benefit the health of the population as a whole.
According to Mitch Zeller, J.D., Director of the FDA’s Center for Tobacco Products, data submitted by Philip Morris Products S.A. showed that marketing the IQOS Tobacco Heating System with the authorized information could help addicted adult smokers transition away from combusted cigarettes, thereby reducing their exposure to harmful chemicals if they completely switch to these products.
(* This product has been authorized to be marketed in USA, and has not yet officially commercialized in Vietnam)
Editor's Recommendations
Most Read Articles
Audrey Abella, 03 Sep 2020
Interim analyses of the INBUILD trial presented at ATS 2020 continue to reflect the benefit of the tyrosine kinase inhibitor nintedanib for individuals with progressive fibrosing interstitial lung diseases (ILDs).
28 Aug 2020
Cơ quan Quản lý Thực phẩm và Dược phẩm Hoa Kỳ (FDA) đã cho phép “Hệ thống làm nóng thuốc lá IQOS” của Philip Morris Products S.A. được kinh doanh dưới hình thức sản phẩm thuốc lá điều chỉnh nguy cơ (Modified Risk Tobacco Products - MRTP) với thông tin “giảm thiểu phơi nhiễm” của cơ thể với chất độc hại.
28 Aug 2020
The U.S. Food and Drug Administration (FDA) has authorized the marketing of Philip Morris Products S.A.’s “IQOS Tobacco Heating System” as modified risk tobacco products (MRTP) with the “exposure modification” order.
Pearl Toh, 5 days ago
Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.